Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Robert Goldman MD, DO, PhD, FAASP Worldhealth.net A new phase 3 trial published in The Lancet reveals that #retatrutide, a nextgeneration GLP3 #agonist, may outperform todays GLP1 drugs in both #diabetes control and weight loss
Usage Instructions: Take exactly as prescribed by your healthcare provider Swallow tablets whole with a small amount of water at least 30 minutes before eating, drinking, or taking other oral medications The typical starting dose is 3mg and adjusted in coordination with tolerability of side effects and effectiveness Maintain a balanced diet and regular exercise program while taking this medication Warnings & Precautions: Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) Use with caution if you have a history of pancreatitis, diabetic retinopathy, or kidney disease Possible side effects include nausea, vomiting, diarrhea, abdominal pain, or decreased appetite
The success rates listed above reflect clinical observations and study data from similar GLP-1 and GIP receptor agonist medications
About the authorView full bio Michael Stewart, MRPharmS Medicine Leaflet Review Manager Contractor, Pharmacist BPharm (Hons), MRPharmS Michael is a community pharmacist practicing in the Midlands and South Yorkshire with more than 20 years experience advising on medicines and medical conditions
Regular monitoring of weight loss velocity and nutritional intake is essential when using both medications concurrently
